BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Turpin A, El Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers (Basel) 2020;12:E3866. [PMID: 33371464 DOI: 10.3390/cancers12123866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.Oncologist. 2020;25:e1701-e1710. [PMID: 32886823 DOI: 10.1634/theoncologist.2020-0577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Li TH, Zhao BB, Qin C, Wang YY, Li ZR, Cao HT, Yang XY, Zhou XT, Wang WB. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Cell Oncol (Dordr) 2021;44:1425-37. [PMID: 34791638 DOI: 10.1007/s13402-021-00651-8] [Reference Citation Analysis]
4 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
5 Group Young Researchers In Inflammatory Carcinogenesis, Wandmacher AM, Mehdorn AS, Sebens S. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers (Basel) 2021;13:4932. [PMID: 34638420 DOI: 10.3390/cancers13194932] [Reference Citation Analysis]
6 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Liu Y, Guo C, Li F, Wu L. LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression. Cell Biochem Funct. 2020;38:58-65. [PMID: 31732974 DOI: 10.1002/cbf.3449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
8 Brancato V, Comunanza V, Imparato G, Corà D, Urciuolo F, Noghero A, Bussolino F, Netti PA. Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer. Acta Biomaterialia 2017;49:152-66. [DOI: 10.1016/j.actbio.2016.11.072] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
9 Wang Z, Qin J, Zhao J, Li J, Li D, Popp M, Popp F, Alakus H, Kong B, Dong Q, Nelson PJ, Zhao Y, Bruns CJ. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics 2020;10:7178-92. [PMID: 32641986 DOI: 10.7150/thno.43093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Schöll-Naderer M, Helm O, Spencker J, Pfeifer L, Rätsch T, Sebens S, Classen B. Plant-derived saccharides and their inhibitory potential on metastasis associated cellular processes of pancreatic ductal adenocarcinoma cells. Carbohydr Res 2020;490:107903. [PMID: 32171073 DOI: 10.1016/j.carres.2019.107903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Laurent-Badr Q, Barbe C, Brugel M, Hautefeuille V, Volet J, Grelet S, Desot E, Botsen D, Deguelte S, Pitta A, Abdelli N, Brasseur M, De Mestier L, Neuzillet C, Bouché O. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. Dig Liver Dis 2020;52:658-67. [PMID: 32362489 DOI: 10.1016/j.dld.2020.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Barhli A, Cros J, Bartholin L, Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig Liver Dis 2018;50:979-90. [PMID: 30205952 DOI: 10.1016/j.dld.2018.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
13 Pouypoudat C, Buscail E, Cossin S, Cassinotto C, Terrebonne E, Blanc JF, Smith D, Marty M, Dupin C, Laurent C, Dabernat S, Chiche L, Vendrely V. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Dig Liver Dis 2019;51:1043-9. [PMID: 31000479 DOI: 10.1016/j.dld.2019.03.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
14 Archibugi L, Graglia B, Valente R, Stigliano S, Roberto M, Capalbo C, Marchetti P, Nigri G, Capurso G. Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. Pancreatology. 2020;20:1149-1154. [PMID: 32800645 DOI: 10.1016/j.pan.2020.07.398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yonemori K, Seki N, Kurahara H, Osako Y, Idichi T, Arai T, Koshizuka K, Kita Y, Maemura K, Natsugoe S. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Cancer Sci 2017;108:124-35. [PMID: 27862697 DOI: 10.1111/cas.13119] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
16 Renard Y, Perrenot C, Labrousse M, Avisse C, Rhaiem R, Piardi T, Braun M, Perez M. Exploration of peripancreatic lymphatic pathways in a live porcine model. Ann Anat 2019;225:57-64. [PMID: 31284072 DOI: 10.1016/j.aanat.2019.06.003] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
18 Védie A, Neuzillet C. Pancreatic cancer: Best supportive care. La Presse Médicale 2019;48:e175-85. [DOI: 10.1016/j.lpm.2019.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Wang G, Pan J, Zhang L, Wei Y, Wang C. Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Cell Prolif 2017;50. [PMID: 28940804 DOI: 10.1111/cpr.12389] [Cited by in Crossref: 51] [Cited by in F6Publishing: 61] [Article Influence: 10.2] [Reference Citation Analysis]
20 Ravi B, Kanwar P, Sanyal SK, Bheri M, Pandey GK. VDACs: An Outlook on Biochemical Regulation and Function in Animal and Plant Systems. Front Physiol 2021;12:683920. [PMID: 34421635 DOI: 10.3389/fphys.2021.683920] [Reference Citation Analysis]
21 Liu L, Zhang N, Dou Y, Mao G, Bi C, Pang W, Liu X, Song D, Deng H. Lysosomal dysfunction and autophagy blockade contribute to IMB-6G-induced apoptosis in pancreatic cancer cells. Sci Rep 2017;7:41862. [PMID: 28139733 DOI: 10.1038/srep41862] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
22 Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget 2018;9:6952-67. [PMID: 29467942 DOI: 10.18632/oncotarget.24084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
23 Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res 2017;23:7263-75. [PMID: 28947567 DOI: 10.1158/1078-0432.CCR-17-0831] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
24 Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacol Ther. 2017;174:145-172. [PMID: 28223233 DOI: 10.1016/j.pharmthera.2017.02.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
25 Lorenzo D, Rebours V, Maire F, Palazzo M, Gonzalez JM, Vullierme MP, Aubert A, Hammel P, Lévy P, Mestier L. Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer. World J Gastroenterol 2019; 25(34): 5082-5096 [PMID: 31558858 DOI: 10.3748/wjg.v25.i34.5082] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
26 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
27 Xu W, Chang J, Du X, Hou J. Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer. Biomed Pharmacother 2017;95:1112-8. [PMID: 28922730 DOI: 10.1016/j.biopha.2017.09.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 9.4] [Reference Citation Analysis]
28 Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Digestive and Liver Disease 2019;51:28-37. [DOI: 10.1016/j.dld.2018.09.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
29 Turpin A, Chevalier H, Neuzillet C. [Maintenance strategies for advanced pancreatic cancer: Rationale and issues]. Bull Cancer 2018;105:739-41. [PMID: 30029762 DOI: 10.1016/j.bulcan.2018.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Lin L, Fan Y, Gao F, Jin L, Li D, Sun W, Li F, Qin P, Shi Q, Shi X, Du L. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy. Theranostics 2018;8:1923-39. [PMID: 29556365 DOI: 10.7150/thno.22834] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 15.0] [Reference Citation Analysis]
31 Cheng D, Fan J, Ma Y, Zhou Y, Qin K, Shi M, Yang J. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Cell Biosci 2019;9:28. [PMID: 30949340 DOI: 10.1186/s13578-019-0290-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
32 Zhou Q, Tao X, Xia S, Guo F, Pan C, Xiang H, Shang D. T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? Front Oncol 2020;10:382. [PMID: 32266154 DOI: 10.3389/fonc.2020.00382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Donahue TR, Dawson DW. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. Trends Endocrinol Metab 2016;27:770-81. [PMID: 27461042 DOI: 10.1016/j.tem.2016.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Fanous M, Keikhosravi A, Kajdacsy-Balla A, Eliceiri KW, Popescu G. Quantitative phase imaging of stromal prognostic markers in pancreatic ductal adenocarcinoma. Biomed Opt Express 2020;11:1354-64. [PMID: 32206415 DOI: 10.1364/BOE.383242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
35 Liu L, Liu Y, Liu X, Zhang N, Mao G, Zeng Q, Yin M, Song D, Deng H. Resibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3. Cancer Sci 2018;109:3611-22. [PMID: 30168902 DOI: 10.1111/cas.13788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
36 Tamburrino D, Crippa S, Partelli S, Archibugi L, Arcidiacono PG, Falconi M, Capurso G. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Dig Liver Dis. 2020;52:392-399. [PMID: 32113888 DOI: 10.1016/j.dld.2020.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
37 Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M, Wu Y, Sun Y. Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas 2019;48:142-50. [PMID: 30640225 DOI: 10.1097/MPA.0000000000001226] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
38 Liu X, Zhong L, Jiang W, Wen D. Repression of circRNA_000684 inhibits malignant phenotypes of pancreatic ductal adenocarcinoma cells via miR-145-mediated KLF5. Pancreatology 2021;21:406-17. [PMID: 33563550 DOI: 10.1016/j.pan.2020.12.023] [Reference Citation Analysis]
39 Archibugi L, Piciucchi M, Stigliano S, Valente R, Zerboni G, Barucca V, Milella M, Maisonneuve P, Delle Fave G, Capurso G. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Sci Rep 2017;7:13024. [PMID: 29026148 DOI: 10.1038/s41598-017-13430-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
40 Tijeras-Raballand A, Hilmi M, Astorgues-Xerri L, Nicolle R, Bièche I, Neuzillet C. Microbiome and pancreatic ductal adenocarcinoma. Clin Res Hepatol Gastroenterol 2021;45:101589. [PMID: 33607375 DOI: 10.1016/j.clinre.2020.101589] [Reference Citation Analysis]
41 Gleeson FC, Kerr SE, Kipp BR, Voss JS, Minot DM, Tu ZJ, Henry MR, Graham RP, Vasmatzis G, Cheville JC, Lazaridis KN, Levy MJ. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Oncotarget. 2016;7:54526-54536. [PMID: 27203738 DOI: 10.18632/oncotarget.9440] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
42 Wang Y, Ding X, Hu H, He Y, Lu Z, Wu P, Tian L, Xia T, Yin J, Yuan H, Shi G, Liu D, Jiang K, Miao Y. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Int J Cancer. 2018;143:3143-3154. [PMID: 29978472 DOI: 10.1002/ijc.31657] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
43 Słotwiński R, Lech G, Słotwińska SM. Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. Cent Eur J Immunol 2021;46:258-63. [PMID: 34764796 DOI: 10.5114/ceji.2021.107027] [Reference Citation Analysis]
44 Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, D'Alessandro A, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget 2017;8:6742-62. [PMID: 28039486 DOI: 10.18632/oncotarget.14272] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
45 Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d’Engremont C, Dupont-gossart A, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. JNCI: Journal of the National Cancer Institute 2017;109. [DOI: 10.1093/jnci/djx037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
46 Jun E, Kim SC, Lee CM, Oh J, Lee S, Shim IK. Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. Sci Rep 2017;7:12381. [PMID: 28959053 DOI: 10.1038/s41598-017-12670-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
47 Yang Z, Senninger N, Flammang I, Ye Q, Dhayat SA. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 2019;145:1165-78. [PMID: 30778748 DOI: 10.1007/s00432-019-02863-w] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Cai J, Liu T, Huang P, Yan W, Guo C, Xiong L, Liu A. USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. Biochem Biophys Res Commun 2017;486:184-90. [PMID: 28286270 DOI: 10.1016/j.bbrc.2017.03.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
49 Vendrely V, Peuchant E, Buscail E, Moranvillier I, Rousseau B, Bedel A, Brillac A, de Verneuil H, Moreau-Gaudry F, Dabernat S. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Lett 2017;390:91-102. [PMID: 28089829 DOI: 10.1016/j.canlet.2017.01.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
50 Gu J, Chen Z, Chen X, Wang Z. Heterogeneous nuclear ribonucleoprotein (hnRNPL) in cancer. Clin Chim Acta 2020;507:286-94. [PMID: 32376323 DOI: 10.1016/j.cca.2020.04.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
51 Xu BQ, Fu ZG, Meng Y, Wu XQ, Wu B, Xu L, Jiang JL, Li L, Chen ZN. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. Oncotarget 2016;7:62177-93. [PMID: 27556697 DOI: 10.18632/oncotarget.11405] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
52 Roger E, Martel S, Bertrand-Chapel A, Depollier A, Chuvin N, Pommier RM, Yacoub K, Caligaris C, Cardot-Ruffino V, Chauvet V, Aires S, Mohkam K, Mabrut JY, Adham M, Fenouil T, Hervieu V, Broutier L, Castets M, Neuzillet C, Cassier PA, Tomasini R, Sentis S, Bartholin L. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Cell Death Dis 2019;10:886. [PMID: 31767842 DOI: 10.1038/s41419-019-2116-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
53 Drifka CR, Loeffler AG, Mathewson K, Keikhosravi A, Eickhoff JC, Liu Y, Weber SM, Kao WJ, Eliceiri KW. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016;7:76197-213. [PMID: 27776346 DOI: 10.18632/oncotarget.12772] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 20.8] [Reference Citation Analysis]
54 Thu PM, Zheng ZG, Zhou YP, Wang YY, Zhang X, Jing D, Cheng HM, Li J, Li P, Xu X. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis. Eur J Pharmacol 2019;850:23-34. [PMID: 30716311 DOI: 10.1016/j.ejphar.2019.01.060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Bian Z, Ji W, Xu B, Huang W, Jiao J, Shao J, Zhang X. The role of long noncoding RNA SNHG7 in human cancers (Review). Mol Clin Oncol 2020;13:45. [PMID: 32874575 DOI: 10.3892/mco.2020.2115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Liu C, Wang J, Yuan X, Qian W, Zhang B, Shi M, Xie J, Shen B, Xu H, Hou Z, Chen H. Long noncoding RNA uc.345 promotes tumorigenesis of pancreatic cancer by upregulation of hnRNPL expression. Oncotarget 2016;7:71556-66. [PMID: 27689400 DOI: 10.18632/oncotarget.12253] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
57 Hu X, Xiao Y, Sun J, Ji B, Luo S, Wu B, Zheng C, Wang P, Xu F, Cheng K, Hua H, Li D. New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors. Acta Pharm Sin B 2021;11:1148-57. [PMID: 34094825 DOI: 10.1016/j.apsb.2020.10.019] [Reference Citation Analysis]
58 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
59 Lenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts JH, Gundlach JP, Helm O, Tiwari S, Weiskirchen R, Rose-John S, Röcken C, Mikulits W, Wenzel P, Schneider G, Saur D, Schäfer H, Sebens S. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Oncoimmunology 2017;7:e1368603. [PMID: 29296518 DOI: 10.1080/2162402X.2017.1368603] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
60 Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151 [PMID: 29853732 DOI: 10.3748/wjg.v24.i20.2137] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 54] [Article Influence: 15.8] [Reference Citation Analysis]
61 Huang B, Liu C, Wu Q, Zhang J, Min Q, Sheng T, Wang X, Zou Y. Long non-coding RNA NEAT1 facilitates pancreatic cancer progression through negative modulation of miR-506-3p. Biochem Biophys Res Commun 2017;482:828-34. [PMID: 27888106 DOI: 10.1016/j.bbrc.2016.11.120] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]